New nebulised tobramycin product launched

Vantobra (tobramycin) is the latest product to be added to the range of nebulised antibiotics available to treat chronic pulmonary infection caused by Pseudomonas aeruginosa in patients with cystic fibrosis.

Vantobra is available as a preservative-free nebuliser solution in single-use 1.7ml ampoules each containing 170mg tobramycin.

The recommended dose for adults and children aged six years and older is 170mg twice daily administered via the Tolero nebuliser handset provided in the pack. As with other nebulised tobramycin preparations, Vantobra should be administered in alternating 28-day cycles of active treatment and rest period. Treatment should be continued for as long as there is clinical benefit.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in